Get the Stockscreener App
8.61
6.11%
-0.56
After Hours:
8.58
-0.03
-0.35%
Sensei Biotherapeutics Inc stock is traded at $8.61, with a volume of 10,189.
It is down -6.11% in the last 24 hours and down -9.84% over the past month.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
See More
Previous Close:
$9.17
Open:
$9.15
24h Volume:
10,189
Relative Volume:
0.32
Market Cap:
$10.86M
Revenue:
-
Net Income/Loss:
$-29.80M
P/E Ratio:
-7.2353
EPS:
-1.19
Net Cash Flow:
$-25.19M
1W Performance:
-14.92%
1M Performance:
-9.84%
6M Performance:
+1.49%
1Y Performance:
-12.16%
1-Day Range:
$8.57
$9.15
1-Week Range:
$8.3312
$12.40
52-Week Range:
$5.00
$18.35
Sensei Biotherapeutics Inc Stock (SNSE) Company Profile
Name
Sensei Biotherapeutics Inc
Sector
Industry
Phone
(240) 243-8000
Address
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare SNSE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNSE
Sensei Biotherapeutics Inc
|
8.61 | 11.57M | 0 | -29.80M | -25.19M | -1.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Sensei Biotherapeutics Inc Stock (SNSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Jun-29-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Mar-01-21 | Initiated | Citigroup | Buy |
| Mar-01-21 | Initiated | Oppenheimer | Outperform |
| Mar-01-21 | Initiated | Piper Sandler | Overweight |
View All
Sensei Biotherapeutics Inc Stock (SNSE) Latest News
Measuring Sensei Biotherapeutics Inc.’s beta against major indicesPortfolio Risk Report & Free Long-Term Investment Growth Plans - newser.com
Published on: 2025-11-03 07:12:45 - newser.com
Identifying reversal signals in Sensei Biotherapeutics Inc.2025 Institutional Moves & Fast Exit and Entry Strategy Plans - newser.com
Is Sensei Biotherapeutics Inc. stock in correction or buying zoneQuarterly Growth Report & AI Forecast Swing Trade Picks - newser.com
How geopolitical tensions affect Sensei Biotherapeutics Inc. stockJuly 2025 Reactions & Free Reliable Trade Execution Plans - newser.com
Can Sensei Biotherapeutics Inc. stock deliver consistent earnings growthAnalyst Downgrade & Weekly High Momentum Picks - newser.com
Using data models to predict Sensei Biotherapeutics Inc. stock movementMarket Risk Report & Reliable Trade Execution Plans - newser.com
How Sensei Biotherapeutics Inc. stock reacts to oil prices2025 Key Lessons & Risk Controlled Stock Alerts - newser.com
Sensei Biotherapeutics Halts Lead Drug Development, Explores Sale Or Merger Options - MSN
What technical charts say about Sensei Biotherapeutics Inc. stock2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - newser.com
Long term hold vs stop loss in Sensei Biotherapeutics Inc.2025 Pullback Review & Fast Entry High Yield Stock Tips - newser.com
Applying big data sentiment scoring on Sensei Biotherapeutics Inc.Weekly Volume Report & Short-Term High Return Strategies - newser.com
How to build a custom watchlist for Sensei Biotherapeutics Inc.Breakout Watch & AI Based Buy/Sell Signal Reports - newser.com
Sensei to ditch its lead candidate and cut workforce amidst strategic review - Yahoo Finance
Sensei Biotherapeutics discontinues cancer drug, explores alternatives By Investing.com - Investing.com Australia
Why hedge funds are buying Sensei Biotherapeutics Inc. stockTrade Volume Summary & Consistent Profit Alerts - newser.com
Custom strategy builders for tracking Sensei Biotherapeutics Inc.Weekly Market Report & AI Enhanced Trade Execution Alerts - newser.com
Is Sensei Biotherapeutics Inc. stock reversal real or fakeMarket Growth Review & Low Risk High Reward Ideas - newser.com
Why Sensei Biotherapeutics Inc. is moving todayWeekly Gains Report & Real-Time Market Sentiment Alerts - newser.com
Published on: 2025-10-31 04:44:02 - newser.com
Leading vs lagging indicators on Sensei Biotherapeutics Inc. performanceWeekly Risk Summary & Capital Efficient Trading Techniques - newser.com
Published on: 2025-10-31 04:26:45 - newser.com
Can momentum traders help lift Sensei Biotherapeutics Inc.Weekly Profit Analysis & Stepwise Entry and Exit Trade Signals - newser.com
Published on: 2025-10-31 04:13:44 - newser.com
Is Sensei Biotherapeutics Inc. (4070) stock protected from inflationJuly 2025 Rallies & Free Safe Entry Trade Signal Reports - newser.com
Published on: 2025-10-31 02:55:10 - newser.com
Published on: 2025-10-31 00:46:42 - newser.com
Published on: 2025-10-31 00:27:27 - newser.com
Published on: 2025-10-31 00:24:15 - newser.com
SNSE Downgraded to Neutral by HC Wainwright & Co. Analyst Matthe - GuruFocus
Sensei Biotherapeutics stock rating downgraded as company halts key drug By Investing.com - Investing.com Canada
Why Is Retail Going Gaga Over INTS Stocks Today? - Stocktwits
Sensei Biotherapeutics (SNSE) Faces Downgrade as Development Pla - GuruFocus
H.C. Wainwright downgrades Sensei on shelving of solnerstotug - TipRanks
Sensei Biotherapeutics stock rises after announcing strategic review By Investing.com - Investing.com Philippines
Sensei Biotherapeutics stock rises after announcing strategic review - Investing.com
Sensei falls as it scraps cancer drug development, plans to sell itself - TradingView
Sensei will not initiate new clinical study for solnerstotug - TipRanks
Sensei Biotherapeutics Initiates Strategic Review to Maximize Shareholder Value - TradingView
Sensei Biotherapeutics discontinues cancer drug, explores alternatives - Investing.com
Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value - The Manila Times
Sensei Biotherapeutics Inc Stock (SNSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):